Comparative Proteomics for the Evaluation of Protein Expression and Modifications in Neurodegenerative Diseases

Int Rev Neurobiol. 2015:121:117-52. doi: 10.1016/bs.irn.2015.05.004. Epub 2015 Jun 19.

Abstract

Together with hypothesis-driven approaches, high-throughput differential proteomic analysis performed primarily not only in human cerebrospinal fluid and serum but also on protein content of other tissues (blood cells, muscles, peripheral nerves, etc.) has been used in the last years to investigate neurodegenerative diseases. Even if the goal for these analyses was mainly the discovery of neurodegenerative disorders biomarkers, the characterization of specific posttranslational modifications (PTMs) and the differential protein expression resulted in being very informative to better define the pathological mechanisms. In this chapter are presented and discussed the positive aspects and challenges of the outcomes of some of our investigations on neurological and neurodegenerative disease, in order to highlight the important role of protein PTMs studies in proteomics-based approaches.

Keywords: Amyotrophic lateral sclerosis; Biomarker; Cerebrospinal fluid; Mass spectrometry; Parkinson's disease; Posttranslational modifications; Two-dimensional electrophoresis.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Ceruloplasmin / metabolism
  • Cytoskeletal Proteins / metabolism
  • Humans
  • Models, Molecular
  • Nervous System Diseases / metabolism
  • Neurodegenerative Diseases / metabolism*
  • Neurodegenerative Diseases / physiopathology*
  • Protein Processing, Post-Translational / physiology*
  • Proteomics*

Substances

  • Biomarkers
  • Cytoskeletal Proteins
  • MYBPH protein, human
  • Ceruloplasmin